MindMaze Therapeutics Holding S.A. (RLFTY) Stock Price & Analysis
MindMaze Therapeutics Holding S.A. (RLFTY) — price $0.1779 (0.00%), as of the Oct 23, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
MindMaze Therapeutics Holding S.A. · RLFTY
MindMaze Therapeutics Holding S.A. is a Swiss-based company focused on developing AI-driven neurotherapeutics and pharmacological solutions for neurological and neuropsychiatric conditions. The company operates as an American Depositary Receipt (ADR) and trades on the OTC Other tier, specializing in solutions for brain injury recovery.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.1779 | |
| Change on the day | 0.00% | |
| 52-week range | $0.1677 – $4.05 | |
| Shares traded on the day | 2.5K |
Price & events
Watch the RLFTY film — every key number, told as a short cinematic story
~2 min · open the film
What is MindMaze Therapeutics Holding (RLFTY), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MindMaze Therapeutics Holding S.A. (RLFTY) is the company analyzed here. It employs 10 people and is led by Zach W. Henderson. In Q2 FY2026 it reported revenue of $744,717 and net income of -$9M.
What do the latest results show for MindMaze Therapeutics Holding (RLFTY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $744,717.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $744,717 | -$9M | -$0.06 (diluted) |
| Q2 FY2025 | $1M | -$4M | -$0.36 (diluted) |
| Q4 FY2024 | $3M | -$13M | -$1.00 (diluted) |
What are the financial strengths and risks for MindMaze Therapeutics Holding (RLFTY)?
Short answer
The distress and quality screens read Altman Z -1.18 · Piotroski F 0. Trailing ratios: current ratio 1.40.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.18 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
MindMaze Therapeutics Holding Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the RLFTY research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is RLFTY a good stock to buy?
Stock Expert AI does not rate RLFTY buy, sell or hold. MindMaze Therapeutics Holding S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RLFTY stock price today?
The last price recorded on this page for MindMaze Therapeutics Holding S.A. (RLFTY) is $0.1779, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks associated with investing in RLFTY?
Investing in RLFTY carries several notable risks specific to its operational model and market listing. A primary concern is its trading on the OTC Other tier, which inherently implies a higher risk profile due to lower disclosure requirements, potentially limited liquidity, and wider bid-ask spreads compared to major exchanges.
What are the key factors to evaluate for RLFTY?
Evaluate RLFTY on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does RLFTY data refresh on this page?
RLFTY's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RLFTY's recent stock price performance?
MindMaze Therapeutics Holding S.A. (RLFTY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in AI-driven neurotherapeutics and pharmacological solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RLFTY overvalued or undervalued right now?
MindMaze Therapeutics Holding S.A. (RLFTY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RLFTY before investing?
Before investing in MindMaze Therapeutics Holding S.A. (RLFTY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (12 figures)
The 12 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 7 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.1779 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T12:24:55.066Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.5K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $744,717 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$9M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 3 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.1677 – $4.05 | UNRECORDED | Stored company-profile observation — Captured 2026-10-24 | |
id.employees | Employees | 10 | UNRECORDED | Stored company-profile observation — Captured 2026-10-24 | |
id.ceo | Chief executive | Zach W. Henderson | UNRECORDED | Stored company-profile observation — Captured 2026-10-24 | |
fin.scores | Distress and quality screens | Altman Z -1.18 · Piotroski F 0 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 1.40 | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.